Halozyme Therapeutics Inc. (NASDAQ: HALO) stock declined by 0.15% at last close whereas the HALO stock gains by 10.04% in the pre-market trading session. Halozyme is a pharmaceutical business that develops revolutionary ways to enhance patient outcomes and experiences for both new and current medicines.
>> 7 Top Picks for the Post-Pandemic Economy <<
HALO stock, Financial Highlights
Halozyme Therapeutics reported its second-quarter 2021 financial results. Here’s the summary:
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
- The revenue generated for the second quarter of 2021 was $136.5 million relative to $55.2 million for Q2 2021.
- The second quarter’s cost of product sales was $23.0 million whereas for the second quarter 2020 it was $5.7 million
- The research and development costs for Q2 2021 were $8.1 million, relative to $9.0 million in the second quarter of 2020.
- For the second quarter of 2021 selling, general, and administrative costs were $12.3 million while the values were $11.0 million in the second quarter of 2020.
- Operating income was $93.0 million on a GAAP basis in the second quarter of 2021, relative to $29.6 million in the second quarter of 2020.
- Net income was $91.5 million on a GAAP basis in the second quarter of 2021, relative to $25.8 million in Q2 of 2020.
- The non-GAAP net income in the second quarter of 2021 was $97.8 million, relative to $33.6 million in the second quarter of 2020.
- On June 30, 2021, cash, cash equivalents, and marketable securities totaled $755.3 million, up from $368.0 million on December 31, 2020.
Read More
Corporate Update
In the second quarter, HALO repurchased about 1.0 million shares of common stock for $48.8 million at an average value of $47.05, meeting its objective of $125 million in share repurchases at an average price of $44.43 in 2021.
HALO stock 2021 Financial Expectations
- Revenues are expected to be between $425 million to $445 million, a rise from the previous estimate of $375 to $395 million, reflecting a 59% to 66% year-over-year increase.
- GAAP Operating Income is anticipated between $260 million to $280 million, an increase of 80 percent to 94 percent year over year.
- GAAP Diluted Earnings per Share of $1.55 to $1.70, up from an earlier forecast of $1.25 to $1.40, reflecting 70 percent to 86 percent year-over-year increase.
- Non-GAAP Diluted Earnings per Share of $1.85 to $2.00, up from an earlier forecast of $1.55 to $1.70, representing 65% to 78% year-over-year increase.
